Ivonescimab Shows 34% Reduction in Death Risk vs. Standard Therapy in China-Only Squamous NSCLC Trial
Data from a China-only trial of ivonescimab were presented May 31, 2026, at the American Society of Clinical Oncology meeting in Chicago and published simultaneously in The Lancet.
StatIvonescimab reduced the risk of death by 34 percent compared with a standard treatment in patients with squamous non-small cell lung cancer, according to trial data presented Sunday. The study was conducted entirely in China by Akeso Therapeutics. The drug combines the activity of two of the best-selling cancer medicines.
It is being developed outside China by Summit Therapeutics. Results were presented at the annual meeting of the American Society of Clinical Oncology in Chicago and published simultaneously in The Lancet. ” Akeso had no comment for this story.
The article was written by Matthew Herper and published May 31, 2026, by STAT as an exclusive STAT+ story.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
nypost.comWHO Reports Five Recoveries From Rare Ebola Strain in Congo and Uganda
The World Health Organization said five people have recovered from the Bundibugyo strain despite the absence of approved treatments or vaccines. At least 906 suspected cases and 223 deaths have been reported across the affected region.
citizen.co.zaEbola Outbreak in Eastern Congo Reaches 906 Suspected Cases
WHO Director-General Tedros Adhanom Ghebreyesus arrived in Bunia on May 30 to assess the response to a Bundibugyo virus outbreak that has killed 223 people. Officials reported cases spreading to North Kivu and South Kivu, while Uganda confirmed nine infections.
France 24Zambia’s Kabwe Residents Sue Mining Company Over Lead Contamination
Children in Kabwe, Zambia, show blood lead levels above World Health Organization limits after decades of mining. An estimated 140,000 women and children have joined a class-action lawsuit against Anglo American South Africa Limited.